Umbilical Cord Mesenchymal Stem Cells Derived Neurospheres Promote Long-term functional recovery But Aggravate Acute Phase Inflammation in Experimental Stroke

Hu, Jiexiang; Chang, Yanmin; Peng, Chunyang; Huang, Sui; Li, Gang; Li, Huiyu

doi:10.1016/j.neuroscience.2021.10.032

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a connection between increased numbers of A1 reactive astrocytes in the injured tissue and pro‐inflammatory cytokines. Moreover, M2 activation of microglia results in the release of glucocorticoids, TGFβ, and IL‐10, which are mediators of anti‐inflammatory activity 79,80 . Different neurodegenerative diseases, such as AD and PD, are also influenced by abnormal activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, an essential component of the innate immune system 76,81,82 …”

Section: Mscs and Neurological Diseasesmentioning

confidence: 99%

Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke

Saleh,

Majeed,

Margiana

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Cerebral ischemic damage is prevalent and the second highest cause of death globally across patient populations; it is as a substantial reason of morbidity and mortality. Mesenchymal stromal cells (MSCs) have garnered significant interest as a potential treatment for cerebral ischemic damage, as shown in ischemic stroke, because of their potent intrinsic features, which include self‐regeneration, immunomodulation, and multi‐potency. Additionally, MSCs are easily obtained, isolated, and cultured. Despite this, there are a number of obstacles that hinder the effectiveness of MSC‐based treatment, such as adverse microenvironmental conditions both in vivo and in vitro. To overcome these obstacles, the naïve MSC has undergone a number of modification processes to enhance its innate therapeutic qualities. Genetic modification and preconditioning modification (with medications, growth factors, and other substances) are the two main categories into which these modification techniques can be separated. This field has advanced significantly and is still attracting attention and innovation. We examine these cutting‐edge methods for preserving and even improving the natural biological functions and therapeutic potential of MSCs in relation to adhesion, migration, homing to the target site, survival, and delayed premature senescence. We address the use of genetically altered MSC in stroke‐induced damage. Future strategies for improving the therapeutic result and addressing the difficulties associated with MSC modification are also discussed.

show abstract

Section: Mscs and Neurological Diseasesmentioning

confidence: 99%

Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke

Saleh,

Majeed,

Margiana

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Moreover, the results of the meta-analysis did not include "brain water content" as indicator of structural outcome. In recent years, an increasing number of studies have tried to explore the ideal subtype and dosage of stem cells, the appropriate time for injections, as well as the best administration route [17][18][19]. Thus, we aimed to perform an updated meta-analysis to provide the most comprehensive evidence relating to the therapeutic effects of stem cells on the functional and structural outcomes in animals exposed to ICH, and better foster the stem cell-based therapy that progressed into clinical translation.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of stem cell therapy in animal models of intracerebral hemorrhage: an updated meta-analysis

Qin

Zeng

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Multiple studies have reported that stem cell therapy has beneficial effects in animal models of intracerebral hemorrhage (ICH). However, this finding remains inconclusive. This study was performed to systematically determine the effect size of stem cell therapy in ICH animal models by pooling and analyzing data from newly published studies. Methods A literature search identified studies of stem cells in animal models of ICH. We searched mainstream databases from inception to November, 2021. And pooled effect size of stem cells was determined for diversified neurobehavioral scales and structural endpoints using random effects models. Results The median quality score of 62 included studies was 5.32. Our results revealed an overall positive effect of stem cell therapy. More specifically, the SMD was − 2.27 for mNSS, − 2.14 for rotarod test, − 2.06 for MLPT, − 1.33 for cylinder test, − 1.95 for corner turn test, − 1.42 for tissue loss, and − 1.86 for brain water content. For mNSS, classifying comparisons by quality score showed significant differences in estimates of effect size (p = 0.013), and high-quality comparisons showed a better outcome (SMD = − 2.57) compared with low-quality comparisons (SMD = − 1.59). Besides, different delivery routes also showed a significant difference in the estimates of effect size for mNSS (p = 0.002), and the intraperitoneal route showed the best outcome (SMD = − 4.63). For tissue loss, the autologous blood-induced ICH model showed a better outcome (SMD = − 1.84) compared with the collagenase-induced ICH model (SMD = − 0.94, p = 0.035). Additionally, stem cell therapy initiated within 8 h post-ICH showed the greatest efficacy on tissue loss reduction, followed by initiated with 24 h post-ICH. Finally, stem cells with different sources and types showed similar beneficial effects for mNSS as well as tissue loss. Conclusions Our results suggested that stem cell therapy had remarkable benefits on ICH animals on both the functional and structural outcomes in animal models of ICH, with very large effect size. These findings support the utility of further studies to translate stem cells in the treatment of ICH in humans. Moreover, the results should be interpreted in the light of the limitations in experimental design and the methodological quality of the studies included in the meta-analysis.

show abstract

Nanoparticle and Stem Cell Combination Therapy for the Management of Stroke

Salatin

Farhoudi

Sadigh‐Eteghad

et al. 2023

CPD

View full text Add to dashboard Cite

Stroke is currently one of the primary causes of morbidity and mortality worldwide. Unfortunately, the available treatments for stroke are still extremely limited. Indeed, stem cell (SC) therapy is a new option for the treatment of stroke that could significantly expand the therapeutic time window of stroke. Some proposed mechanisms for stroke-based SC therapy are the incorporation of SCs into the host brain to replace dead or damaged cells/tissues. Moreover, acute cell delivery can inhibit apoptosis and decrease lesion size, providing immunomudolatory and neuroprotection effects. However, several major SC problems related to SCs such as homing, viability, uncontrolled differentiation, and possible immune response, have limited SC therapy. A combination of SC therapy with nanoparticles (NPs) can be a solution to address these challenges. NPs have received considerable attention in regulating and controlling the behavior of SCs because of their unique physicochemical properties. By reviewing the pathophysiology of stroke and the therapeutic benefits of SCs and NPs, we hypothesize that combined therapy will offer a promising future in the field of stroke management. In this work, we discuss recent literature in SC research combined with NP-based strategies that may have a synergistic outcome after stroke incidence.

show abstract

Umbilical Cord Mesenchymal Stem Cells Derived Neurospheres Promote Long-term functional recovery But Aggravate Acute Phase Inflammation in Experimental Stroke

Cited by 5 publications

References 43 publications

Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke

Therapeutic gene delivery by mesenchymal stem cell for brain ischemia damage: Focus on molecular mechanisms in ischemic stroke

Efficacy of stem cell therapy in animal models of intracerebral hemorrhage: an updated meta-analysis

Nanoparticle and Stem Cell Combination Therapy for the Management of Stroke

Contact Info

Product

Resources

About